Literature DB >> 11221042

[Ultrasonography of the upper urinary tract in patients with spinal cord injury].

G Virgili1, E Finazzi Agrò, A Giannantoni, A D'Amico, S Germani, F Petta, G Vespasiani.   

Abstract

A lesion of the upper urinary tract (UUT) is a possible outcome of the bladder dysfunction following a spinal cord injury (SCI). The most common findings are hydronephrosis, bladder-ureteral reflux and pyelonephritis. Aim of the study was to evaluate the prevalence of UUT abnormalities, evaluable by ultrasound (US), in a population of SCI patients; furthermore we correlated the presence of such abnormalities to clinical findings. We evaluated 115 consecutive patients who underwent US scan of UUT. Mean time between injury and our evaluation was 81.5 +/- 100.2 months. Lesion level was cervical (38/115), dorsal (59/115) and lumbar (18/115). Eight patients emptied their bladder spontaneously, 105 by means of intermittent catheterization, while 2 were wearing indwelling catheter. Seventy-four patients used anticholinergics drugs. It was evaluated the presence of: hydronephrosis, renal stones and chronic pyelonephritis using US. Afterward the presence of such alterations was correlated to sex and age of patients, time between injury and our evaluation, method of bladder emptying and use of anticholinergics drugs. In 25/115 patients (21.7%) were found abnormalities of UUT. A significative correlation was found between presence of UUT lesions and older age. In our series, prevalence of UUT abnormalities observed by means of US in SCI patients is 21.7%. This finding could be due to correct management and strict follow up of the patients.

Entities:  

Mesh:

Year:  2000        PMID: 11221042

Source DB:  PubMed          Journal:  Arch Ital Urol Androl        ISSN: 1124-3562


  1 in total

1.  Abdominal ultrasonography findings in patients with spinal cord injury in Korea.

Authors:  Ji Cheol Shin; Chang-il Park; Sang Hyun Kim; Eun Joo Yang; Eun Joo Kim; Dong Wook Rha
Journal:  J Korean Med Sci       Date:  2006-10       Impact factor: 2.153

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.